|Rapid review complete
|In combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|A full HTA is not recommended. The NCPE recommends that durvalumab not be considered for reimbursement at the submitted price*
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.